J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference.

The OIG report points to gaps in documentation and decision-making transparency, particularly in the case of Aduhelm, where FDA records indicated only 13 meetings with Biogen, but congressional ...

By providing clearer nutrition information, the FDA hopes to empower consumers to make more informed food choices and contribute to long-term healthier eating patterns across the US.